Last reviewed · How we verify

Bisphonal (INCADRONIC ACID)

Astellas Pharma · FDA-approved active Small molecule Quality 26/100

Bisphonal (generic name: INCADRONIC ACID) is a incadronic acid Small molecule drug developed by Astellas Pharma. It is currently FDA-approved for Humoral hypercalcemia of malignancy, Osteoporosis.

At a glance

Generic nameINCADRONIC ACID
SponsorAstellas Pharma
Drug classincadronic acid
TargetFarnesyl pyrophosphate synthase
ModalitySmall molecule
Therapeutic areaBone
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bisphonal

What is Bisphonal?

Bisphonal (INCADRONIC ACID) is a incadronic acid drug developed by Astellas Pharma, indicated for Humoral hypercalcemia of malignancy, Osteoporosis.

What is Bisphonal used for?

Bisphonal is indicated for Humoral hypercalcemia of malignancy, Osteoporosis.

Who makes Bisphonal?

Bisphonal is developed and marketed by Astellas Pharma (see full Astellas Pharma pipeline at /company/astellas).

What is the generic name of Bisphonal?

INCADRONIC ACID is the generic (nonproprietary) name of Bisphonal.

What drug class is Bisphonal in?

Bisphonal belongs to the incadronic acid class. See all incadronic acid drugs at /class/incadronic-acid.

What development phase is Bisphonal in?

Bisphonal is FDA-approved (marketed).

What does Bisphonal target?

Bisphonal targets Farnesyl pyrophosphate synthase and is a incadronic acid.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing